Novo Nordisk presented data from three separate studies that highlighted the efficacy of oral semaglutide, an investigational once-daily glucagon-like peptide-1 (GLP-1) analog in a pill. Additionally, data showed the efficacy of Merck’s Januvia on type 2 diabetes patients age 65 and older in comparison to the SGLT2 inhibitor dapagliflozin.
Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.
PhaseBio Pharmaceuticals’ antiplatelet drug PB2452 received Breakthrough Therapy designation from the U.S. FDA.
Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.
Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.
Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.
Eli Lilly’s new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending the company’s shares to a record high and weighing on those of arch-rival Novo Nordisk.
Eli Lilly signed a licensing deal for Chugai Pharmaceutical’s oral non-peptidic GLP-1 receptor agonist OWL833.
Denmark-based Zealand Pharma announced that the company’s Phase III trial for dasiglucagon for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints, setting up potential regulatory approval.
Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogs may be effective treatments for Parkinson’s disease.